Laboratory evaluation of anti-biofilm agents for use in dental unit waterlines.
Dental unit waterline biofilm has been recognized as a potential point of contamination and a risk to patients with any level of immunocompromise. Biofilm in dental unit waterlines, once established, has proven formidable to efforts in disinfection/disruption. This project compared standardized evaluation techniques by assessing the efficacy of a variety of agents that have been reported or suggested as useful in surface disinfection and/or antiseptic protocols. The zones of inhibition, minimum inhibitory/bactericidal concentrations and use-dilution with stainless steel carrier replicates tests assessed the disinfection of planktonic organisms using standardized microbial testing procedures. The disruption and/or disinfection of planktonic and biofilm organisms within naturally occurring dental unit waterlines were evaluated by culture and scanning electron microscopy. The six commercially available antimicrobial agents used to assess the techniques were bleach (sodium hypochlorite), Cavicide, glutaraldehyde, Listerine Antiseptic, Peridex and Sterilex Ultra. Comparisons between the results for each technique evaluated were determined for each product. All six agents demonstrated antimicrobial efficacy at the working concentrations designated by the manufacturers. Biofilm matrix elimination evaluated by scanning electron microscopy found virtually 0% elimination by glutaraldehyde to an estimated 90% elimination by Sterilex Ultra and bleach after one treatment. Treatment with Cavicide, Listerine Antiseptic and Peridex resulted in negligible elimination of the biofilm matrix. For comparability, the use of standardized testing techniques to evaluate a disinfection agent's efficacy against dental unit waterline contamination is essential. This project demonstrates a model system for evaluating disinfection agents potentially useful in the management of dental unit waterline biofilm, and should assist in educating the dental clinician in the appraisal of existing and future product claims.
Meiller
T F
TF
Baltimore College of Dental Surgery, University of Maryland, Baltimore, MD, USA. tfm001@dental.umaryland.edu
Kelley
J I
JI
Baqui
A A
AA
DePaola
L G
LG
D018441:Biofilms / Q000187:drug effects*; D002710:Chlorhexidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002733:Chlorophenols / Q000494:pharmacology; D015169:Colony Count, Microbial; D019551:Dental Disinfectants / Q000494:pharmacology*; D003748:Dental Equipment; D004203:Disinfection / Q000379:methods; D004338:Drug Combinations; D005976:Glutaral / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D009930:Organic Chemicals; D012459:Salicylates / Q000494:pharmacology; D012973:Sodium Hypochlorite / Q000494:pharmacology; D013729:Terpenes / Q000494:pharmacology; D014871:Water Microbiology
D002733:Chlorophenols; D019551:Dental Disinfectants; D004338:Drug Combinations; D009930:Organic Chemicals; D012459:Salicylates; C440248:Sterilex Ultra; D013729:Terpenes; C103359:cavicide; C057473:Listerine; D012973:Sodium Hypochlorite; C010882:chlorhexidine gluconate; D002710:Chlorhexidine; D005976:Glutaral